Andrew Reardon, Chief Legal Officer & Secretary, on September 03, 2026, sold 5,000 shares in Ligand Pharmaceuticals (LGND) for $1,430,434. Following the Form 4 filing with the SEC, Reardon has control over a total of 36,514 common shares of the company, with 36,514 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/886163/000200101126000137/xslF345X05/edgardoc.xml